证券代码：688310 证券简称：迈得医疗 公告编号：2026-010 迈得医疗工业设备股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、2025年度主要财务数据和指标 单位：万元 ■ 注：1.本报告期初数与法定披露的上年年末数一致。 2.以上财务数据及指标以合并报表数据填列，但未经会计师事务所审计，具体数据以公司2025年年度报 告为准。 3.以上数据如有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 2025年公司实现营业收入44,741.90万元，与去年同期相比上升62.79%；实现营业利润5,969.89万元，利 润总额6,122.32万元，实现归属于母公司所有者的净利润6,525.99万元，实现归属于母公司所有者的扣除 非经常性损益的净利润5,329.23万元，与去年同期相比变动较大，实现扭亏为盈。 报告期末，公司总资产118,704.03万元，与去年同期相比上升12.69%；归属于母公司的所有者权益 86 ...

2025年度，公司整体营业收入实现大幅增长，主要系公司统筹推进生产计划有序落地，保障了产品有效 交付，并且坚持技术创新与工艺迭代双轮驱动，持续强化产品竞争力与市场影响力，血液净化类和药械 组合类智能装备业务发展良好，尤其得益于药械组合类医用耗材在终端市场展现出良好的需求增长态 势，对应药械组合类智能装备市场需求前景乐观，公司重点围绕药械组合类智能装备展开新产品研发和 市场开拓，本期药械组合类智能装备收入实现较大增长。 智通财经APP讯，迈得医疗(688310.SH)发布2025年度业绩快报，2025年公司实现营业收入4.47亿元，与 去年同期相比上升62.79%;实现归属于母公司所有者的净利润6525.99万元，实现归属于母公司所有者的 扣除非经常性损益的净利润5329.23万元，与去年同期相比变动较大，实现扭亏为盈。 ...

Core Viewpoint - The recent financial report of Liansheng Chemical (301212) shows a year-on-year increase in total revenue and net profit, but a decline in quarterly performance, highlighting concerns over accounts receivable and cash flow [1][4]. Financial Performance - Total revenue for the first half of 2025 reached 343 million yuan, a 13.95% increase compared to 301 million yuan in the same period of 2024 [1]. - Net profit attributable to shareholders was 18.02 million yuan, up 9.61% from 16.44 million yuan in the previous year [1]. - The gross margin decreased to 12.67%, down 4.93% year-on-year, while the net margin fell to 5.42%, a decline of 5.25% [1]. - The total of selling, administrative, and financial expenses was 14.44 million yuan, representing 4.21% of revenue, an increase of 34.68% year-on-year [1]. Cash Flow and Receivables - The company reported a significant accounts receivable level, with accounts receivable amounting to 95.82 million yuan, which is 555.2% of the net profit for the latest annual report [1][4]. - Operating cash flow per share improved to 0.47 yuan, a substantial increase of 146.47% compared to -1.01 yuan in the previous year [1]. Business Model and Industry Outlook - The company's return on invested capital (ROIC) was 0.34% last year, indicating weak capital returns, while the historical median ROIC since listing is 12.26% [3]. - The chemical industry has shown signs of recovery, with improved market demand for major products, although the pace of recovery varies across different segments [5]. - The company plans to enhance production efficiency and optimize existing product processes while advancing new biodegradable materials to diversify its product offerings and create new profit growth points [5].